Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

November 2021 – Lung Cancer

Looking at Lung Cancer without Stigma
In her introduction to this special issue on Lung Cancer, Lillie emphasizes that we need to inspire and help people to stop smoking, and get rid of the overall stigma surrounding this disease. Read More ›

Becoming a Patient Advocate After a Small-Cell Lung Cancer Diagnosis at Age 28
Montessa Lee’s pain persisted after an initial visit to the doctor and a misdiagnosis. Finally, an x-ray in the emergency room revealed a 15-cm mass on her left lung. Read how she turned anger into action. Read More ›

Immunotherapy Beneficial in Patients with Early-Stage Non–Small-Cell Lung Cancer and PD-L1 Expression
For the first time, the use of immunotherapy after surgical removal of the tumor and chemotherapy has shown benefits in patients with early-stage non–small-cell lung cancer (NSCLC) and PD-L1 expression, a biomarker found in some patients with NSCLC. Read More ›

Tecentriq First Immunotherapy Approved for Adjuvant Treatment of Patients with Early-Stage NSCLC and PD-L1 Expression
On October 15, 2021, the FDA approved a new indication for Tecentriq (atezolizumab) for adjuvant (additional) treatment of patients with stage II-IIIA non–small-cell lung cancer and PD-L1 expression, after surgical removal of the tumor and chemotherapy. This is the first immunotherapy approved for patients with early-stage lung cancer. Read More ›

The Pandemic Is Not Over: Staying Connected and Receiving Encouragement While Living with Lung Cancer
On his lonely journey dealing with lung cancer, Ron Simmons found that connecting with others who had lung cancer helped him create a sense of purpose and gave him a mission moving forward. Read More ›

Exkivity Second FDA-Approved Oral Targeted Therapy for Patients with Metastatic NSCLC and EGFR Exon 20 Insertion Mutations
On September 15, 2021, the FDA approved Exkivity (mobocertinib) capsules, an oral kinase inhibitor, for the treatment of adults with locally advanced or metastatic non–small-cell lung cancer (NSCLC) and EGFR exon 20 insertion mutations whose disease progressed during or after platinum-based chemotherapy, a cancer with few treatment options. Read More ›

Clinical Trial Aims to Reduce Malnutrition in Patients with Lung Cancer
Combating malnutrition should be at the forefront of cancer care, as studies have shown that up to 80% of patients with cancer are malnourished at some point during their treatment. Dr. Spees describes a new clinical trial focused on improving the nutrition of patients with lung cancer. Read More ›

Advances in the Treatment of Patients with NSCLC and Genetic Mutations or with Small-Cell Lung Cancer
Although most of the drugs being developed for lung cancer these days are for non–small-cell lung cancer (NSCLC), there may be a shift on the horizon as new treatment options emerge for patients with small-cell lung cancer. Read More ›

Getting the Most Out of Your Treatment: Your Role in Achieving Desired Outcomes in the Patient Journey
Nurse practitioner Beth Faiman, PhD, MSN, an expert in multiple myeloma, briefly discusses the unique features of this uncurable but very treatable cancer, highlighting that getting what you want out of treatment requires arming yourself with knowledge about the disease, evaluating your treatment goals, familiarizing yourself with your treatment team, and becoming an active participant in your treatment. Read More ›

New Study Shows Causes of Lung Cancer in People Who Never Smoked
It has become increasingly clear that lung cancer can be caused by different factors, including some environmental chemicals. Lung cancer in never smokers under the microscope. Read More ›

Page 1 of 2